Investor Presentation

January 2024



©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

Legal Disclaimers

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about the sufficiency of our existing cash resources through topline data for the Phase 3 DAVIO 3 clinical trials; our expectations regarding the timing and clinical development of our product candidates, including EYP-1901 and EYP-2301; the potential for EYP-1901 as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration, non-proliferative diabetic retinopathy and diabetic macular edema; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to access needed capital; termination or breach of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of guidelines, recommendations and studies; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.



Committed to developing therapeutics to improve the lives of patients with serious retinal diseases

Pipeline represents multi billion-dollar opportunities using our bioerodible Durasert E[™] IVT delivery technology

- **EYP-1901** vorolanib, a selective and patented TKI in Durasert E[™]
 - Positive topline Phase 2 data in wet AMD
 - First Phase 3 trial in wet AMD planned to initiate in 2H 2024
 - Topline Phase 2 data in **NPDR** anticipated in Q2 2024
 - First patient dosed in Phase 2 trial in DME; topline data anticipated in Q1 2025
- EYP-2301 razuprotafib, a patented TIE-2 agonist for serious retinal diseases in Durasert E[™]

Durasert[®] - proven, safe IVT drug delivery technology

- Bioerodible Durasert E[™] and non-erodible formulations
- Safely administered to thousands of patient eyes across four FDA approved products with non-erodible formulations

Strong Balance Sheet

- **~\$330M** of cash and investments on December 31, 2023
- Cash runway through topline data for Phase 3 wet AMD pivotal trials



Pipeline Represents Multibillion Dollar Product Opportunities

Durasert E [™] Programs	Indication	Discovery	Pre-Clin	Phase 1	Phase 2	Phase 3	Next Milestone
	Wet AMD			maintenance t positive Phase			EOP2 Mtg with FDA, Phase 3 initiation in 2H 2024
EYP-1901 – vorolanib in Durasert E™ (tyrosine kinase inhibitor)	NPDR	sin	ngle-dose, 9-mc 77 patie				Topline data in Q2 2024
	DME	single	-dose, 6-month	treatment			Topline data in Q1 2025
EYP-2301 – razuprotafib in Durasert E™ (TIE-2 agonist)	serious retinal diseases						Pre-clin tox and PK data in 2024
Complement inhibition	GA						Potential product candidate in 2024
 6 6 9 9	- AND	patient		<i>trial underway</i> cular degeneration; EOF tive diabetic retinopath			EYEPOINT.

Durasert - Intravitreal Sustained-Release Drug Delivery

TECHNOLOGY DURASERT®



Safe, Sustained IVT Drug Delivery

- Delivered via a standard in-office IVT injection
- Continuous, stable release of drug
- Zero-order kinetics

Durasert E[™]: bioerodible

- Insert consists of drug embedded within a bioerodible matrix
- Designed to deplete drug load before matrix fully erodes
- RETISERT^{®2}

ILUVIEN^{®1}

YUTIQ^{®1}

VITRASERT^{®2}

Durasert[®]: non-erodible

bioerodible matrix


covered with non-

Drug embedded within a

erodible polyimide shell:

Vorolanib Brings a Potential New MOA to the Treatment of VEGF-Mediated Retinal Diseases by Blocking all Isoforms of VEGF and PDGF

- Potent and selective pan–VEGF receptor inhibition
- Composition of matter patent into 2037 (potential patent term extension to 2042)
- Demonstrated neuroprotection in a validated retinal detachment animal model
- Blocks PDGF which may lead to antifibrotic benefit
- Reduced off-target binding does not inhibit TIE-2 at clinically relevant doses




SoC, standard of care; ANG, angiopoietin; PDGF(R), platelet-derived growth factor (receptor); PLGF, placental growth factor; TIE-2, tyrosine-protein kinase receptor TIE-2; VEGF(R), vascular endothelial growth factor (receptor).



6 • ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EYP-1901: Receptor Binding Vorolanib In Bioerodible Durasert E[™]



- Delivered in the physician office via standard intravitreal injection technique
- Immediately bioavailable featuring an initial burst of drug followed by zero order kinetics release for ~9 months
- **Positive efficacy** data in wet AMD from Phase 1 DAVIO and Phase 2 DAVIO 2 clinical trials
- Favorable safety data in ongoing Phase 2 clinical trials
- Shipped and stored at **ambient temperature**



Phase 2 DAVIO 2 Clinical Trial Topline Results

A NON-INFERIORITY TRIAL VERSUS AN AFLIBERCEPT CONTROL





©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

The DAVIO 2 Clinical Trial

A non-inferiority trial evaluating two doses of EYP-1901 against an aflibercept control in wet AMD The DAVIO 2 clinical trial was designed to evaluate EYP-1901 in wet AMD and support Phase 3 clinical trials based on a Type C meeting with FDA

Design: Multi-center, randomized, double-masked trial in patients with previously treated wet AMD

Anti-VEGF supplement criteria:


- 5 letter loss with 75 microns of new fluid
- Other criteria
 - 10 letter loss due to wet AMD
 - 100 microns new fluid x 2 visits
 - New retinal hemorrhage from wet AMD
 - Investigator discretion

Primary outcome: difference in mean change in BCVA from Day 1 to Week 28 and 32 (blended)

Key secondary endpoints: safety, reduction in treatment burden, percent of eyes supplement-free up to six months and anatomical results



DAVIO 2 Clinical Trial is Randomized, Double-Masked, Aflibercept Controlled* with a Single EYP-1901 Treatment at Two Doses



10 • ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

*Aflibercept on-label control required by FDA



DAVIO 2 Patient Baseline Characteristics Well Balanced Across Arms

	Aflibercept 2mg q8W (n=54)	EYP-1901 2mg (n=50)	EYP-1901 3mg (n=52)
Mean age, years (range)	75.9 (52-93)	76.4 (61-93)	75.4 (56-89)
Female, %	53.7%	64.0%	67.3%
Mean BCVA, ETDRS letters (range)	73.4 (41-85)	73.9 (52-84)	74.9 (46-85)
Mean CST, µm (range)	265.7 (178-348)	267.0 (192-400)	262.9 (186-345)
Median length of time for wet AMD diagnosis prior to screening, months (range)	28.1 (2.4-273.6)	24.2 (2.4-168.0)	28.1 (2.4-145.2)
Mean # of injections normalized to 12 months prior to screening (range)	9.5 (2.0-12.0)	10.1 (2.0-13.0)	10.0 (2.0-13.3)

11 • ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.



EYP-1901 Phase 2 DAVIO 2 Clinical Trial Met All Objectives

Endpoint	Achieved Endpoint?	2mg	3mg
Primary : Non-inferior change in BCVA vs. aflibercept	\checkmark	- 0.3 letters	- 0.4 letters
Secondary: Favorable safety profile ¹	\checkmark	No EYP-1901	related SAEs
Secondary: Reduction in Treatment Burden vs. 6 mos prior	\checkmark	89%	85%
Secondary: Reduction in Treatment Burden vs. aflibercept	\checkmark	83%	79%
Secondary: Supplement-free up to 6 months	\checkmark	65% 88% of eyes had 0 or only 1 supplemental injections	64% 83% of eyes had 0 or only 1 supplemental injections
Secondary: Anatomical control vs aflibercept	\checkmark	+9.7um	+5.2um

12 • ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

1. As of November 7, 2023 data cut PRELIMINARY DATA – PENDING FINAL ANALYSIS



DAVIO 2 Achieved Primary Endpoint of Non-Inferiority Change in Visual Acuity in Both EYP-1901 Arms; Statistically and Numerically Non-Inferior to Control (95% CI)

	EYP-1901 2mg	EYP-1901 3mg	Aflibercept 2mg q8W
Change in BCVA* vs. Baseline	+ 1.0 letters	+ 0.9 letters	+ 1.3 letters
Difference vs. Aflibercept Control	- 0.3 letters	- 0.4 letters	NA
Statistics	NI (95% CI)	NI (95% CI)	NA

Non-inferiority Margin = - 4.5 letters per FDA guidance

In the Pulsar trial, HD Eylea (16-week 8mg arm) change in BCVA vs. 2mg Eylea was -1.4 letters¹

13 • ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

*Blended week 28 and week 32

1 – AAO 2022 presentation, Paolo Lanzetta, on behalf of the PULSAR study investigators NI, Non-inferior; CI, Confidence Interval

PRELIMINARY DATA - PENDING FINAL ANALYSIS



EYP-1901 was Statistically Non-Inferior in Change in BCVA Compared to the Aflibercept Control (95% CI)

MEAN CHANGE IN BCVA FROM BASELINE

Diff vs. Aflibercept Control 15 EYP-1901 2mg - 0.3* 10 **ETRDS** letters EYP 1901 3mg - 0.4* 5 +1.3* +1.0* +0.9*Change in -5 -10 -15 Randomization Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8** (EYP-1901 insert) aflibercept control (N=53)

In the Pulsar trial, HD Eylea (16-week 8mg arm) change in BCVA vs. 2mg Eylea was -1.4 letters¹

*Blended week 28 and week 32 change vs. baseline **Month 8 represents 6 months after first EYP-1901 injection

1 - AAO 2022 presentation, Paolo Lanzetta, on behalf of the PULSAR study investigators

14 • ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

- CI, Confidence Interval
- PRELIMINARY DATA PENDING FINAL ANALYSIS



EYP-1901 Demonstrated a Favorable Safety Profile in the Phase 2 DAVIO 2 Clinical Trial¹

- No reported EYP-1901-related ocular or systemic SAEs
 - Four ocular SAEs reported in a study eye none deemed EYP-1901 related²
- >97% of AEs reported were mild (Grade 1 or 2) and generally expected with IVT
- No insert migration into the anterior chamber
- No retinal occlusive vasculitis
- Low patient discontinuation rate of 4% up to week 32
 - No discontinuations were related to EYP-1901 treatment

SAE, serious adverse event; AE, adverse event; IVT, intravitreal injection PRELIMINARY DATA CUT– PENDING FINAL ANALYSIS



In the Phase 2 DAVIO 2 Trial the Reported SAEs Occurred After an Aflibercept Injection or Paracentesis and Were Deemed Unrelated to EYP-1901¹

Four ocular SAEs reported in study eyes – all determined to be unrelated to EYP-1901²

- 1. Retinal detachment at week 1; **one week after initial aflibercept injection**, prior to EYP-1901 injection
- Bacterial endophthalmitis at week 32; two days after anterior chamber paracentesis in a patient using CPAP
- 3. Non-infectious endophthalmitis at week 29; seven days after aflibercept injection
- 4. Retinal tears at week 36; four weeks after aflibercept injection



EYP-1901 was Well Tolerated - AE's Generally Mild and Self-Limiting Through Six Months

N (%)	Aflibercept 2mg q8W (n=54)	EYP-1901 2mg (n=53)	EYP-1901 3mg (n=53)
Study eyes with ≥1 ocular AE	20 (37.0%)	30 (56.6%)	29 (54.7%)
Ocular AEs reported in ≥5% of study eyes:			
Worsening wet AMD	2 (3.7%)	7 (13.2%)	6 (11.3%)
Conjunctival hemorrhage	2 (3.7%)	6 (11.3%)	3 (5.7%)
Vitreous floaters	0 (0.0%)	3 (5.7%)	4 (7.5%)
Retinal hemorrhage	1 (1.9%)	1 (1.9%)	5 (9.4%)
Cataract	3 (5.6%)	2 (3.8%)	3 (5.7%)
Eye pain	1 (1.9%)	2 (3.8%)	3 (5.7%)
Vitreous detachment	2 (3.7%)	3 (5.7%)	2 (3.8%)
Subretinal fluid	1 (1.9%)	3 (5.7%)	0 (0.0%)



In DAVIO 2, the Safety Profile of EYP-1901 was Comparable with the Safety Profile of Intravitreal Anti-VEGF Therapies

	VABYSMO (HD EYLEA (aflibercept 8mg)	
N (%)	AVENUE*1 N=262	STAIRWAY*2 N=71	CANDELA ³ (Treatment-emergent AEs only)** N=106
Study eyes with ocular AEs	125 (47.7%)	28 (39.4%)	40 (37.7%)
Study eyes with serious ocular AEs	5 (1.9%)	0 (0.0%)	3 (2.8%)

*Multiple occurrences of the same event in one individual counted only once. In the AVENUE study, 214 (81.7%) participants experienced at least one adverse event during the study. In the STAIRWAY study, 54 (76.1%) of participants experiences at least one adverse event during the study.

**Data reflects treatment-emergent AEs only. Overall AEs not reported.

18 • ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

Sources: 1. Jama Ophthalmology, *Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration*, Jayashree Sahni, MBBS, MD; Pravin U. Dugel, MD; Sunil S. Patel, MD, PhD; et al. 2. Jama Ophthalmology, *Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration*, Arshad M. Khanani, MD, MA; Sunil S. Patel, MD, PhD; Philip J. Ferrone, MD; et al. 3. Jama Ophthalmology, *Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration*, Charles C. Wykoff, MD, PhD¹; David M. Brown, MD¹; Kimberly Reed, OD²; et al.



EYP-1901 Continues to Show a Favorable Safety Profile Across Multiple Clinical Trials

- Summary: DAVIO (Phase 1): DAVIO 2 (Phase 2)¹: PAVIA (Phase 2)¹:
- 17 patients treated
- 102 patients treated
- ~51 patients treated

~170 treated patients with a minimum of six months post EYP-1901 injection with no EYP-1901-related ocular or systemic SAE's



Clinically Meaningful Reduction in Treatment Burden Supports EYP-1901 as a Maintenance Treatment For Wet AMD

	EYP-1901 2mg	EYP-1901 3mg
Mean number of injections week 8 through week 32	0.55	0.71
Mean number of injections 6 months prior to screening*	5.07	4.98
Reduction in treatment burden vs. 6 months prior (%)	89%	85%



EYP-1901 Demonstrated a Meaningful Reduction in Treatment Burden vs. the Aflibercept Control Arm

	EYP-1901 2mg	EYP-1901 3mg	Aflibercept 2mg q8W
Mean number of injections week 8 through week 32	0.55	0.71	3.32
Reduction in treatment burden vs. aflibercept control (%)	83%	79%	NA



EYP-1901 Demonstrated Clinically Meaningful Supplement-Free Rates

PERCENT OF PATIENTS SUPPLEMENT-FREE UP TO SIX MONTHS AFTER ADMINISTRATION OF EYP-1901

	EYP-1901 2MG	EYP-1901 3mg
Supplement-Free Rates	65% 88% of eyes had 0 or only 1 supplemental injections	64% 83% of eyes had 0 or only 1 supplemental injections



Nearly Two-Thirds of Eyes Treated with EYP-1901 were Supplement-Free up to Six Months After a Single Injection

SUMMARY OF SUPPLEMENT-FREE RATES BY MONTH




Stable Anatomy via OCT in EYP-1901 Arms

	EYP-1901 2mg	EYP-1901 3mg	Aflibercept 2mg q8W
Baseline CST (mean)	262.9	267.0	265.7
Change in OCT at Week 32 vs. Baseline	+ 15.1 microns	+ 10.6 microns	+ 5.4 microns
Difference vs. Aflibercept Control	+ 9.7 microns	+ 5.2 microns	NA

- Based on market research, CST within approximately 30-50 microns is an acceptable range for the potential adoption of a new treatment
- The standard deviation on the measure is 10 microns; anything under 10 microns is within the margin of error



Data from DAVIO 2 Suggests Strong Anatomic Control with OCT Change Below 10 microns at Week 32 Compared to the Aflibercept Control






Phase 2 DAVIO 2 Sub-Group Analysis of Patients Anti-VEGF Supplement-Free Up to 6 Months






EYP-1901 Demonstrated Numerical Superiority in Change in BCVA in Sub-Group Analysis of Patients Supplement-Free Up to 6 Months

SUB-GROUP ANALYSIS OF PATIENTS SUPPLEMENT-FREE UP TO SIX MONTHS MEAN CHANGE IN BCVA FROM BASELINE



27

Strong Anatomic Control in Patients with No Supplement Up to Month 8 with OCT Change Below 10 microns Compared to the Aflibercept Control





EYP-1901 Phase 2 DAVIO 2 Clinical Trial Met All Primary and Secondary Endpoints

Endpoint	DAVIO 2 Topline	DAVIO 2 Lower Limit (as included in November deck)
Mean change in BCVA vs. aflibercept control	 - 0.3 letters (EYP-1901 2mg) - 0.4 letters (EYP-1901 3mg) Statistically non-inferior (CI 95%) 	< - 3.0 letters (potentially underpowered)
Safety	 No reported EYP-1901-related ocular SAEs¹ No reported EYP-1901- related systemic SAEs¹ 	Favorable safety profile
Reduction in treatment burden	 89% (EYP-1901 2mg)* 85% (EYP-1901 3mg)* 	50% or better
Supplement-free rate	 65% (EYP-1901 2mg), 88% 0-1 supplements 64% (EYP-1901 3mg), 83% 0-1 supplements 	50% or better
Mean change in CST on OCT	 + 15.1 microns (EYP-1901 2mg) + 10.6 microns (EYP-1901 3mg) 	Within ~30 microns

1. As of November 7, 2023 data cut

29 • ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

*vs. mean number of injections normalized 6 months prior to screening PRELIMINARY DATA – PENDING FINAL ANALYSIS



Preliminary Phase 3 Pivotal Trial Overview

A NON-INFERIORITY TRIAL VERSUS AN AFLIBERCEPT CONTROL






Positive DAVIO 2 Data Supports Advancement to Non-Inferiority Phase 3 Pivotal Trials in Wet AMD

- DAVIO 2 and Phase 3 Pivotal trials plans were informed by Type C meeting with FDA and consistent with subsequent wet AMD draft guidance for non-inferiority clinical trials
- The Phase 3 non-inferiority trial design is similar to DAVIO 2 except:
 - **Reinjection** of EYP-1901 at six-month intervals
 - Primary efficacy endpoint at **12 months blended** (basis of NDA submission)
 - Safety monitored for up to 24 months; NDA submission planned with 12-month safety data
 - Aflibercept control arm potentially dosed for initial 12 months only
- Two registration trials: parallel US and OUS
 - DAVIO 2 statistics with high CI suggests meaningfully smaller sized and lower cost Phase 3 trials
 - EYP-1901 dosing likely 1 or 2 inserts (vs 2 or 3 in DAVIO 2)
- Initiation of the first pivotal trial anticipated in 2H 2024



EYP-1901 Wet AMD Non-Inferiority Phase 3 Trial Concept: Randomized, Double-Masked, Aflibercept Control – 12 Month Endpoint








EYP-1901: vorolanib in Durasert E™

NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) – PHASE 2 PAVIA CLINICAL TRIAL





EYP-1901 Phase 2 PAVIA Clinical Trial is a Randomized Double-Masked, EYP-1901 Single Injection with Sham Control as a 9-Month Treatment in NPDR



- Moderately severe to severe NPDR patients enrolled
 - Primary endpoint is <u>>2 step</u>
 DRSS improvement score
 at week 36
- Secondary endpoints:
 - Reduction in visionthreatening complications
 - DME occurrence and/or proliferative disease
 - Retinal ischemia
 - Safety

• ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.



PAVIA Masked Safety Summary ¹

Key findings:

- ⊘ No drug-related ocular SAEs
- \odot No drug-related systemic SAEs
- ⊘ Two ocular SAEs, deemed not EYP-1901 related by investigators:
 - Hemorrhagic posterior vitreous detachment (PVD) in a study eye eight-weeks after dosing
 - Macular edema leading to vision loss in the non-study fellow eye

Topline data anticipated in Q2 2024






EYP-1901: vorolanib in Durasert E™

PHASE 2 VERONA CLINICAL TRIAL IN DIABETIC MACULAR EDEMA (DME)





Phase 2 VERONA Clinical Trial is a Randomized, Open-Label, Aflibercept Controlled Trial with a Single EYP-1901 Injection



- Potential 6-month treatment in previously treated DME patients
- Objectives:
 - Evaluate the safety and efficacy of two doses of EYP-1901 in the DME patient population
 - Collect dose-ranging data to inform future clinical trials
- Primary endpoint: time to supplemental anti-VEGF injection up to week 24
- Secondary endpoints: Change in BCVA vs. aflibercept control, stable anatomical outcome as measured by OCT, DRSS over time

EYEPOINT

37 • ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

VERONA Primary Endpoint: Time to Supplemental Injection up to Week 24 – Supplement Criteria

Starting at Week 4:

- Reduction in BCVA ≥10 letters due to DME¹
- Reduction in BCVA of 5-9 letters <u>and</u> >75 microns of new fluid at two consecutive visits¹
- Increase of ≥100 microns of new fluid vs. Baseline (Day 1)²
- Investigator discretion

Starting at Week 12:

Lack of 10% reduction in CST compared to Baseline (Day 1)



EYP-2301: razuprotafib in Durasert E[™]

A SUSTAINED DELIVERY TIE-2 AGONIST FOR SEVERE RETINAL DISEASES






EYP-2301: Razuprotafib in Durasert E[™] is Being Developed as a Sustained Delivery Treatment for Serious Retinal Diseases

EYP-2301 targets vascular endothelial protein tyrosine phosphatase (VE-PTP) to promote TIE-2 activation and maintain vascular stability in the retina

- Tie-2 activation combined with VEGF inhibition has the potential to enhance efficacy and extend durability¹ of treatment
- In the retina, activated TIE-2 controls endothelial cell proliferation, barrier function and intercellular contacts, stabilizing vessels and the blood-retinal barrier²
- Razuprotafib (f/k/a AKB-9778) delivered subcutaneously was previously studied demonstrating preclinical and clinical proof of concept in posterior segment disease ^{3,4}





Solid balance sheet with cash runway through topline data of Phase 3 trials for EYP-1901 in wet AMD

Strong Cash Position

- ~\$330M of cash and investments on December 31, 2023
- \$230M equity financing completed December 2023

Multiple key data and value inflection points within the next 12 months



Continued Execution And Well Funded Through Key EYP-1901 Milestones

EYP-1901

DAVIO 2 enrollment complete	Q1 2023
PAVIA enrollment complete	Q2 2023
DAVIO 2 topline data	December 2023
VERONA - DME Phase 2 Trial initiation	Q1 2024
EOP2 meeting with FDA for wet AMD	March/April 2024
PAVIA topline data	Q2 2024
First wet AMD Phase 3 trial initiation	2H 2024
VERONA topline data	Q1 2025
Corporate	
	PAVIA enrollment complete DAVIO 2 topline data VERONA - DME Phase 2 Trial initiation EOP2 meeting with FDA for wet AMD PAVIA topline data First wet AMD Phase 3 trial initiation

- ✓ YUTIQ transacted for \$82.5M plus royalties
 - Debt retired and cash runway extended into 2025
 - Oversubscribed \$230M equity financing closed

Q2 2023 Q2 2023 December 2023

 \checkmark

Investor Presentation

January 2024



©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.